Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

FLOW

- Among patients with with T2D and CKD, semaglutide reduced the risk of clinically important kidney outcomes, major CV events, and death from any cause. This mortality signal was further substantiated by clinically relevant benefits observed across a broad range of other cardiovascular-kidney outcomes.
- These benefits reflect important clinical effects on kidney, CV, and survival outcomes among high-risk patients, particularly given the reassuring safety findings, and support a therapeutic role for semaglutide in this population.

FLOW

Shown are cumulative incidence plots of the primary outcome, major kidney disease events (a composite of the onset of kidney failure [dialysis, transplantation, or an eGFR of <15 ml per minute per 1.73 m^2 of body-surface area], ≥50% reduction in eGFR from baseline, or death from kidney-related or CV causes) and several confirmatory secondary outcomes: kidney-specific components of the primary outcome (persistent ≥50% reduction in eGFR, persistent eGFR of <15 ml per minute per 1.73 m^2, initiation of long-term renal-replacement therapy, or death from kidney-related causes), death from CV causes, total eGFR slope, major CV events (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from CV causes), and death from any cause.



NO. AT RISK									
Placebo	1766	1736	1682	1605	1516	1408	1048	660	354
Semaglutide	1767	1738	1693	1640	1572	1489	1131	742	392

NO. AT RISK									
Placebo	1766	1736	1682	1605	1516	1408	1048	660	354
Semaglutide	1767	1738	1693	1640	1572	1489	1131	742	392

CKM, cardiovascular-kidney-metabolic; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure.

Perkovic V,, et al..*N Engl J Med.* 2024;391(2):109-121.

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

FLOW

c Death from Cardiovascular Causes



NO. AT RISK

Placebo	1766	1737	1697	1641	1601	1544	1185	772	437
Semaglutide	1767	1739	1703	1665	1627	1583	1234	838	460

d Total eGFR Slope



NO. AT RISK

Placebo	1766	1663	1573	1609	1490	1441	1284	876	609	199
Semaglutide	1766	1665	1590	1606	1521	1468	1345	952	651	218

e First Major Cardiovascular Event



NO. AT RISK

Placebo	1766	1721	1663	1583	1535	1478	1133	731	418
Semaglutide	1767	1725	1672	1622	1575	1515	1176	793	430

f Death from Any Cause



NO. AT RISK

Placebo	1766	1737	1697	1641	1601	1544	1185	772	437
Semaglutide	1767	1739	1703	1665	1627	1583	1234	838	460

CKM, cardiovascular-kidney-metabolic; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure.

Perkovic V,, et al..*N Engl J Med.* 2024;391(2):109-121.